|View printer-friendly version|
Spring Bank Submits IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors
“STING agonists have the potential to become an important immunotherapeutic approach for the treatment of multiple cancers. The availability of an intravenously-administered STING agonist could significantly expand the number of cancers and patients in which such an immunotherapeutic agent could be utilized. Importantly, this approach may be able to overcome the need for intra-tumoral administration observed with the first-generation STING agonist approaches,” said
Part 1 of the SB 11285 IV Phase 1 trial is a dose-escalation study with monotherapy followed by combination with a checkpoint inhibitor and is designed to determine a recommended phase 2 dose. Part 2 of the trial will explore SB 11285 in combination with a checkpoint inhibitor in selected responsive tumor types based on initial anti-tumor activity. The trial will be conducted at multiple sites in
“The filing of the SB 11285 IND application represents another significant achievement for
Mr. Driscoll continued, “We have the financial resources to allow us to advance our clinical programs toward several meaningful value inflection points. Our clinical development programs have the potential to deliver multiple catalysts for our company over the next 3-15 months. We believe that progressing these programs and delivering promising clinical data is the best way to create long-term value for shareholders, and we are focused on achieving those objectives.”
About SB 11285
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.
McNeil, Gray & Rice
Source: Spring Bank Pharmaceuticals, Inc.